IL142929A0 - Local delivery of drugs to the colon for local treatment of colonic diseases - Google Patents

Local delivery of drugs to the colon for local treatment of colonic diseases

Info

Publication number
IL142929A0
IL142929A0 IL14292999A IL14292999A IL142929A0 IL 142929 A0 IL142929 A0 IL 142929A0 IL 14292999 A IL14292999 A IL 14292999A IL 14292999 A IL14292999 A IL 14292999A IL 142929 A0 IL142929 A0 IL 142929A0
Authority
IL
Israel
Prior art keywords
local
colon
drugs
colonic diseases
treatment
Prior art date
Application number
IL14292999A
Original Assignee
Dexxon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dexxon Ltd filed Critical Dexxon Ltd
Publication of IL142929A0 publication Critical patent/IL142929A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL14292999A 1998-11-12 1999-11-12 Local delivery of drugs to the colon for local treatment of colonic diseases IL142929A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/190,127 US6231888B1 (en) 1996-01-18 1998-11-12 Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
PCT/IL1999/000607 WO2000028974A1 (en) 1998-11-12 1999-11-12 Local delivery of drugs to the colon for local treatment of colonic diseases

Publications (1)

Publication Number Publication Date
IL142929A0 true IL142929A0 (en) 2002-04-21

Family

ID=22700115

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14292999A IL142929A0 (en) 1998-11-12 1999-11-12 Local delivery of drugs to the colon for local treatment of colonic diseases

Country Status (5)

Country Link
US (1) US6231888B1 (en)
EP (1) EP1131058A1 (en)
AU (1) AU1175000A (en)
IL (1) IL142929A0 (en)
WO (1) WO2000028974A1 (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022683B1 (en) * 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US6531152B1 (en) * 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
EP2266542A3 (en) * 1998-10-01 2013-07-31 Elan Pharma International Limited Controlled release nanoparticulate compositions
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
KR100762475B1 (en) * 1998-11-27 2007-10-04 칸지 타카다 An Oral Formulation for Gastrointestinal Drug Delivery
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US6432979B1 (en) * 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
SE0000773D0 (en) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (en) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US8101200B2 (en) 2000-04-13 2012-01-24 Angiotech Biocoatings, Inc. Targeted therapeutic agent release devices and methods of making and using the same
CA2406383A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research A.beta.42 lowering agents
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
CN1285333C (en) * 2000-06-07 2006-11-22 张昊 Colon-releasing oral preparation and its preparing method
US6689760B1 (en) 2000-07-10 2004-02-10 Enzrel Inc. Anti-mycobacterial compositions
US6455073B1 (en) 2000-07-10 2002-09-24 Enzrel, Inc. Covalent microparticle-drug conjugates for biological targeting
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
EP1411900B2 (en) * 2001-06-01 2013-12-04 Pozen, Inc. PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
SE0102993D0 (en) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
EP1314776B1 (en) * 2001-11-23 2007-05-23 Rohm And Haas Company Optimised pellet formulations
US7550156B2 (en) * 2001-11-23 2009-06-23 Rohm And Haas Company Optimised pellet formulations
WO2003053402A1 (en) * 2001-12-20 2003-07-03 Pharmacia Corporation Zero-order sustained released dosage forms and method of making the same
EP1474108A2 (en) * 2002-01-09 2004-11-10 Enzrel, Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
EP1428528A1 (en) * 2002-09-27 2004-06-16 Tiense Suikerraffinaderij N.V. Synergistic combinations of dietary fiber and NSAIDs for the treatment of cancer
CA2501324A1 (en) * 2002-10-30 2004-05-21 Pharmacia Corporation Oral extended release tablets and methods of making and using the same
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc Method and composition for treating neurodegenerative disorders
ES2214130B1 (en) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 2-3'-BIPIRIDINES.
ES2214129B1 (en) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-FENILFURAN-2-ONAS.
ES2213485B1 (en) * 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. DERIVATIVES OF 2-FENILPIRAN-4-ONA.
EP1618883A4 (en) * 2003-04-25 2009-07-08 Kouki Bussan Yugenkaisha Agent for preventing and ameliorating constipation
US20040248858A1 (en) * 2003-06-09 2004-12-09 Parghi Kaumil H. Cure for cancer
EP1651195A4 (en) * 2003-07-11 2007-10-03 Myriad Genetics Inc Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
WO2005011708A1 (en) * 2003-07-31 2005-02-10 The Board Of Regents Of The University Of Texas System Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers
SI21638A (en) * 2003-11-12 2005-06-30 LEK farmacevtska družba d.d. Pharmaceutical form with controlled release of ketopfofen
ATE554752T1 (en) 2004-02-06 2012-05-15 Pharmatel R & D Pty Ltd As Trustee For The Pharmatel R & D Trust USE OF AMINOSALICYLATES IN IRRITABLE BOWEL SYNDROME WITH DIARRHEA AS THE PREMIUM SYMPTOM
US7642400B2 (en) * 2004-03-08 2010-01-05 Mayo Foundation For Medical Education And Research Protein kinase C iota
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
AU2005241023A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
CA2467894A1 (en) * 2004-05-20 2005-11-20 Medical Futures Inc. A composition for prevention and treatment of colon adenomas
JP5009152B2 (en) * 2004-05-28 2012-08-22 サリックス ファーマシューティカルズ， インコーポレイテッド Prevention, treatment, and recovery of radiation-induced enteritis
US8129359B2 (en) 2004-06-04 2012-03-06 Ethicon, Inc. Composition and method for treating post-surgical pain
US8377906B2 (en) * 2004-06-04 2013-02-19 Ethicon, Inc. Compositions and methods for preventing or reducing postoperative ileus and gastric stasis
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006102439A2 (en) * 2005-03-23 2006-09-28 Florida Atlantic University Treatment or prevention of cancer and precancerous disorders
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
WO2007014124A2 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
EP2529729A1 (en) * 2005-08-24 2012-12-05 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture thereof
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
WO2007146920A2 (en) 2006-06-13 2007-12-21 Ethicon, Inc. Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
WO2008044236A2 (en) * 2006-10-10 2008-04-17 Dexcel Pharma Technologies Ltd. Improved release of statins in the intestine
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
WO2009021104A2 (en) * 2007-08-08 2009-02-12 Cavanaugh Brian J Method and apparatus for delivery of a ligating suture
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
EP2179727B1 (en) * 2008-10-27 2013-05-29 Roquette Freres Water insoluble polymer: modified starch derivative-based film coatings for colon targeting
WO2010056741A2 (en) * 2008-11-12 2010-05-20 Auspex Pharmaceuticals, Inc. Phenylacetic acid inhibitors of cyclooxygenase
CN102638978A (en) * 2009-06-25 2012-08-15 波曾公司 Method for treating a patient in need of aspirin therapy
EP2445499A4 (en) 2009-06-25 2013-02-27 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
EP2616051A1 (en) 2010-07-29 2013-07-24 Cosmo Technologies Ltd. Pharmaceutical and/or dietary compositions based on short chain fatty acids
US9433583B2 (en) 2011-04-22 2016-09-06 Frank J. Farrell Colon vitamin
UA115139C2 (en) 2011-12-28 2017-09-25 Поузен Інк. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
MA40687A (en) * 2014-04-10 2017-03-28 Ifom Fondazione St Firc Di Oncologia Molecolare VASCULAR MALFORMATION TREATMENT METHODS AND COMPOSITIONS
US10182993B2 (en) 2015-04-06 2019-01-22 Patheon Softgels Inc. Compositions for colonic delivery of drugs
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN108401418B (en) * 2016-11-17 2023-05-26 上海交通大学医学院 Oral colon targeted delivery system and preparation method and application thereof
EP3593266A4 (en) * 2017-03-07 2021-01-13 Anivive Lifesciences, Inc. Drug discovery platform
US20220072013A1 (en) * 2018-12-21 2022-03-10 Ca*Tx, Inc. Pharmaceutical Combinations for the Treatment of Cancer

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
JPS5186117A (en) 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
GB1538075A (en) 1975-03-24 1979-01-10 Champion Paper Co Ltd Formation of microcapsules by interfacial cross-linking and microcapsules produced thereby
US4277364A (en) 1975-12-22 1981-07-07 The United States Of America As Represented By The Secretary Of Agriculture Encapsulation by entrapment
US4344857A (en) 1975-12-22 1982-08-17 The United States Of America As Represented By The Secretary Of Agriculture Encapsulation by entrapment
US4169804A (en) 1976-08-19 1979-10-02 Minnesota Mining And Manufacturing Company Magnetically responsive composite microparticle
DE2712161C2 (en) 1977-03-19 1983-01-05 Blendax-Werke R. Schneider Gmbh & Co, 6500 Mainz Dental and oral care products
US4307717A (en) 1977-11-07 1981-12-29 Lectec Corporation Sterile improved bandage containing a medicament
US4279812A (en) 1979-09-12 1981-07-21 Seton Company Process for preparing macromolecular biologically active collagen
JPS5911563B2 (en) 1980-02-27 1984-03-16 日本原子力研究所 Method for manufacturing multilayer sustained release composites
US4348384A (en) 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US4349530A (en) 1980-12-11 1982-09-14 The Ohio State University Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal
US4442655A (en) 1981-06-25 1984-04-17 Serapharm Michael Stroetmann Fibrinogen-containing dry preparation, manufacture and use thereof
JPS59222406A (en) 1983-06-01 1984-12-14 Teijin Ltd Pharmaceutical preparation for remedying periodontosis and its preparation
CA1196863A (en) 1983-06-08 1985-11-19 Mattheus F.A. Goosen Slow release injectable insulin composition
AU2698684A (en) 1983-07-01 1985-02-07 Battelle Memorial Institute Polypeptide biodegradable et son utilisation pour le relargage progressif de medicaments
MX163953B (en) 1984-03-27 1992-07-03 Univ New Jersey Med PROCEDURE FOR PREPARING A BIODEGRADABLE COLLAGEN MATRIX
US4619913A (en) 1984-05-29 1986-10-28 Matrix Pharmaceuticals, Inc. Treatments employing drug-containing matrices for introduction into cellular lesion areas
US4678516A (en) 1984-10-09 1987-07-07 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
US4568536A (en) 1985-02-08 1986-02-04 Ethicon, Inc. Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition
US4794002A (en) 1985-11-01 1988-12-27 Monsanto Company Modified polymeric surfaces and process for preparing same
US4803075A (en) 1986-06-25 1989-02-07 Collagen Corporation Injectable implant composition having improved intrudability
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
IL98087A (en) 1990-05-04 1996-11-14 Perio Prod Ltd Colonic drug delivery system
SE9002339L (en) 1990-07-04 1992-01-05 Kabi Pharmacia Ab THERAPEUTIC COMPOSITION AND PROCEDURE FOR ITS PREPARATION
AU659106B2 (en) 1990-11-06 1995-05-11 Fgn, Inc. Method for treating colonic polyps by the use of esters and amides of substituted phenyl and pyridyl amino carboxylates
AU650689B2 (en) 1990-11-06 1994-06-30 Fgn, Inc. Esters and amides of substituted indenyl acetic acids
AU658373B2 (en) 1990-11-06 1995-04-13 Fgn, Inc. Esters and amides of substituted pyrrole acetic acids
AU650914B2 (en) 1990-11-06 1994-07-07 Fgn, Inc. Esters and amides of substituted phenyl acetic acids
AU659107B2 (en) 1990-11-06 1995-05-11 Fgn, Inc. Method for treating colonic polyps by the use of esters and amides of substituted fused ring phenyl acetic acids
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
DE69202721T2 (en) 1991-03-08 1995-10-12 Fgn Inc Substituted indenyl compounds.
US5401774A (en) 1991-03-08 1995-03-28 University Of Arizona Method for treating patients with precancerous lesions by administering substituted sulfonyl idenyl acetic and propionic acids and esters to patients with lesions sensitive to such compounds
AU2140492A (en) 1991-05-14 1992-12-30 Biopure Corporation Use of hemoglobin in a method for the treatment of tumors with chemotherapeutic agents
DE4236025A1 (en) 1992-10-24 1994-04-28 Merck Patent Gmbh Oral dosage forms
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5651983A (en) 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
EP0724441A1 (en) 1993-10-19 1996-08-07 The Procter & Gamble Company Picosulphate dosage form
US5514663A (en) 1993-10-19 1996-05-07 The Procter & Gamble Company Senna dosage form
US5498608A (en) 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5622948A (en) 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
WO1997003659A1 (en) 1995-07-20 1997-02-06 Uwe Juergens Use of a non-steroidal anti-inflammatory drug for topical and systemic treatment of acute and chronic polypoid rhinosinusitis
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
WO1999018938A1 (en) * 1997-10-09 1999-04-22 Perio Products Ltd. Delayed total release gastrointestinal drug delivery system

Also Published As

Publication number Publication date
EP1131058A1 (en) 2001-09-12
WO2000028974A1 (en) 2000-05-25
US6231888B1 (en) 2001-05-15
AU1175000A (en) 2000-06-05

Similar Documents

Publication Publication Date Title
IL142929A0 (en) Local delivery of drugs to the colon for local treatment of colonic diseases
PL354540A1 (en) Drugs for the treatment of malignant tumours
IL149224A0 (en) Hydrogen-driven drug dosage form
EP1139746A4 (en) Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
IL196301A0 (en) Medicament for the treatment of hapatitis c
HUP0004286A3 (en) Use of quinazoline derivatives for producing pharmaceutical compositions for treating colonic polyps
PL342515A1 (en) Drug administering device
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
IL147217A0 (en) New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain
EP1311261A4 (en) Medicaments for chemotherapeutic treatment of disease
HUP0104963A3 (en) Compositions for the treatment of skin diseases
AU7728698A (en) Oral formulations for treatment of bacteria-induced diseases of the colon
IL147946A0 (en) Treatment of inflammatory or malignant disease using dnazymes
HUP0201667A2 (en) Oral form of administration
GB2333042B (en) Colonic delivery of weak acid drugs
IL121647A0 (en) Pharmaceutical compositions for the treatment of ocular inflammations comprising dexamethasone palmitate
EP1114642A4 (en) Drugs for periodontal diseases
ZA984650B (en) Intratumoral administration of triphenylethylenes for the treatment of cancer
IL153439A0 (en) Medicines for the prevention and treatment of neurodegenerative diseases
PL325509A1 (en) Therapeutic agent for oral administration
HUP0000569A3 (en) Use of equilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states
IL141339A0 (en) Liquid pharmaceutical for oral delivery
SI1242060T1 (en) Treatment of metastatic disease
GC0000176A (en) Pharmaceutical combination preparations for the treatment of cardiac disorders
HUP0104491A3 (en) Use of amtolmetin guacyl for the production of anti-inflammatory drugs for intestinal inflammations

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
FF Patent granted
KB Patent renewed